perchance Daklinza Side Effects Generic Name: daclatasvir Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Drug Images Support Group Q & A Pricing & Coupons Note: This document contains side effect information about daclatasvir. Some of the dosage forms listed on this page may not apply to the brand name Daklinza. For the Consumer Applies to daclatasvir: oral tablet Along with its needed effects, daclatasvir (the active ingredient contained in Daklinza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking daclatasvir: Incidence not known Chest pain or discomfort lightheadedness, dizziness, or fainting slow or irregular heartbeat unusual tiredness Some side effects of daclatasvir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them: More common Headache nausea Less common Diarrhea For Healthcare Professionals Applies to daclatasvir: oral tablet General In clinical trials, this drug was used in combination with sofosbuvir (with or without ribavirin), with peginterferon alfa/ribavirin, with asunaprevir, or with asunaprevir/peginterferon alfa/ribavirin. Fatigue, headache, and nausea were reported most often when used with sofosbuvir. Headache, anemia, fatigue, and nausea were reported most often when used with sofosbuvir and ribavirin. Fatigue, headache, pruritus, insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia, rash, asthenia, irritability, myalgia, anemia, pyrexia, cough, dyspnea, neutropenia, diarrhea, and arthralgia were reported most often when used with peginterferon alfa/ribavirin; the most common side effects of at least grade 3 severity were neutropenia, anemia, thrombocytopenia, and lymphopenia. The side effects and laboratory abnormalities reported with this drug in combination with peginterferon alfa/ribavirin was similar to those reported with peginterferon alfa/ribavirin alone, including in patients with cirrhosis. Headache, fatigue, diarrhea, nasopharyngitis, and nausea were reported most often when used with asunaprevir. Fatigue, headache, pruritus, asthenia, influenza-like illness, insomnia, rash, anemia, cough, dry skin, diarrhea, nausea, alopecia, irritability, pyrexia, and myalgia were reported most often when used with asunaprevir/peginterferon alfa/ribavirin. The manufacturer product information for coadministered hepatitis C virus (HCV) antiviral drugs should be consulted. [ Ref ] Other Very common (10% or more): Fatigue (up to 41.5%), asthenia (up to 24.1%), influenza-like illness (up to 22.4%), pyrexia (up to 16.1%) Common (1% to 10%): Hot flush, pain, weight decreased [ Ref ] Nervous system Very common (10% or more): Headache (up to 31.2%) Common (1% to 10%): Dizziness, migraine, somnolence [ Ref ] Dermatologic Erythema multiforme has been reported with this drug as part of an asunaprevir regimen. [ Ref ] Very common (10% or more): Pruritus (up to 26.1%), rash (up to 20.6%), dry skin (up to 17.8%), alopecia (up to 16.1%) Postmarketing reports: Erythema multiforme [ Ref ] Psychiatric Very common (10% or more): Insomnia (up to 22.4%), irritability (up to 16.1%) Common (1% to 10%): Depression, anxiety [ Ref ] Hematologic Very common (10% or more): Anemia (up to 20%), neutropenia (up to 14.8%) Common (1% to 10%): Thrombocytopenia, decreased hemoglobin Frequency not reported: Eosinophilia [ Ref ] Of the patients reporting anemia, 43% received ribavirin in addition to this drug and sofosbuvir. During the study, anemia was not reported in the ribavirin-free treatment groups. In trials of this drug with sofosbuvir (with or without ribavirin), grade 3 decreased hemoglobin was reported in 2% of patients; all of these patients received this drug with sofosbuvir and ribavirin. [ Ref ] Respiratory Very common (10% or more): Cough (up to 18.3%), nasopharyngitis (up to 13.7%), dyspnea (up to 12.3%) Common (1% to 10%): Exertional dyspnea, nasal congestion, upper respiratory tract infection [ Ref ] Gastrointestinal Very common (10% or more): Diarrhea (up to 17.6%), nausea (up to 16.6%) Common (1% to 10%): Upper abdominal pain, abdominal pain, constipation, flatulence, gastroesophageal reflux disease, dry mouth, vomiting, elevated lipase [ Ref ] Elevated lipase (at least 3.1 times the upper limit of normal [3.1 x ULN]) was reported in up to 4% of patients using this drug with sofosbuvir (with or without ribavirin). [ Ref ] Musculoskeletal Very common (10% or more): Myalgia (up to 15.3%), arthralgia (up to 10.1%) Common (1% to 10%): Back pain [ Ref ] Metabolic Very common (10% or more): Decreased appetite (up to 11.8%) [ Ref ] Cardiovascular Serious symptomatic bradycardia has been reported in patients taking amiodarone who started therapy with sofosbuvir in combination with another HCV direct-acting antiviral (including this drug). Cases of severe bradycardia and heart block have been reported with this drug in combination with sofosbuvir and concomitant amiodarone and/or other drugs that lower heart rate. [ Ref ] Postmarketing reports: Symptomatic bradycardia, heart block, cardiac arrhythmias [ Ref ] Hepatic Increased ALT (at least 5.1 x ULN), AST (at least 5.1 x ULN), and total bilirubin (at least 2.6 x ULN) were reported in up to 4%, up to 3%, and up to 8% of patients, respectively. Grade 3/4 increased total bilirubin was reported in 5% of patients; all of these patients were coinfected with HIV and using concomitant atazanavir, had Child-Pugh A, B, or C cirrhosis, or were post-liver transplant. [ Ref ] Common (1% to 10%): Increased ALT, increased AST, increased total bilirubin Postmarketing reports: Hepatitis B reactivation [ Ref ] Genitourinary Common (1% to 10%): Urinary tract infection Ocular Common (1% to 10%): Dry eye [ Ref ] References 1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 2. "Product Information. Daklinza (daclatasvir)." Bristol-Myers Squibb, Princeton, NJ. 3. Cerner Multum, Inc. "Australian Product Information." O 0 Some side effects of Daklinza may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA . Next Dosage Print this page More about Daklinza (daclatasvir) Side Effects During Pregnancy Dosage Information Drug Images Drug Interactions Support Group Pricing & Coupons En Español 10 Reviews Add your own review/rating Drug class: NS5A inhibitors Consumer resources Daklinza Daklinza (Advanced Reading) Professional resources Daklinza (AHFS Monograph) Daklinza (FDA) Related treatment guides Hepatitis C Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.} Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Bristol-Myers Squibb Company Drug Class NS5A inhibitors Related Drugs Hepatitis C Harvoni , Epclusa , ribavirin , Zepatier , Mavyret , Sovaldi , sofosbuvir , ledipasvir / sofosbuvir , Vosevi , Viekira Pak , daclatasvir , Pegasys , Intron A , Ribasphere , Olysio , sofosbuvir / velpatasvir , Rebetol , simeprevir , Moderiba , PegIntron , elbasvir / grazoprevir , glecaprevir / pibrentasvir , Roferon-A , More... Daklinza Rating 10 User Reviews 9.8 /10 10 User Reviews 9.8 Rate it! Daklinza Images Daklinza 30 mg (BMS 213) View all images} } cutting-edge
shunned Daklinza Side Effects most appropriate
EmoticonEmoticon